The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...

The biopharmaceutical company agreed to buy Aliada in a deal that adds a potential therapy for Alzheimer’s disease to ...

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

AbbVie acquires Aliada Therapeutics for $1.4 billion, enhancing Alzheimer's R&D with innovative blood-brain barrier ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...